GLP-1 research, from the labels and from sellers’ own pages
Two kinds of page, and every one is listed below: readings of the FDA documents for semaglutide and tirzepatide, and counts of what GLP-1 sellers publish on their own pages and what they leave off.
- 7
- pages read from FDA documents
- 6
- findings counted from sellers' own pages
What the FDA documents say
7 pages, each sourced to FDA-approved prescribing information or an FDA page and quoted with that document’s own date.
- Semaglutide vs tirzepatidereading the label
What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.
- Dose escalation schedulesreading the label
The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.
- Side effect ratesreading the label
What each label reports for nausea, vomiting, diarrhea and constipation — and the sentence every label prints above those numbers.
- Missed dose rulesreading the label
The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.
- Drug interactionsreading the label
Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.
- Buying one onlinereading the label
The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.
- Who should not take onereading the label
The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.
What sellers publish
6 counts of what sellers published and what they left out, each over its own denominator. The findings index explains which set each one counts over, and why.
- How many sellers publish a price
What happened when the pages of every GLP-1 seller we could find were opened and read: how many published a figure at all, and how many published one that can be compared.
Counted over 588 sellers whose pages were opened.
- What drug the price is for
Whether a published GLP-1 figure says which drug it prices, and how often the number sits on a page that never names one.
Counted over 3018 published figures across 408 sellers.
- Compounded or branded
How often a seller says, beside the figure, whether the drug is compounded or the FDA-approved product — and the one case where it almost always does.
Counted over 3018 published figures across 408 sellers.
- What sellers do not publish
The pharmacy, the product class, the dose schedule and the cancellation terms: four things a reader needs before buying, counted as absences with a denominator attached.
Counted over 60 sellers whose figure states what it buys.
- The tirzepatide premium
What the same seller charges for tirzepatide against semaglutide — and why most sellers who sell both do not publish a pair a reader can put side by side.
Counted over 46 sellers publishing a figure for both molecules.
- What a price buys, by dose
Whether a GLP-1 price changes with the dose, and how many sellers publish a figure that states which dose it buys at all.
Counted over 60 of 117 sellers on this roster.